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Background and Objectives: Few studies have reported the drug retention rate (DRR)
of biologic drugs in juvenile idiopathic arthritis (JIA), and none of them has specifically
investigated the DRR of interleukin (IL)-1 inhibitors on systemic JIA (sJIA). This study
aims to describe IL-1 inhibitors DRR and evaluate predictive factors of drug survival
based on data from a real-world setting concerning sJIA.
Methods: Medical records from sJIA patients treated with anakinra (ANA) and
canakinumab (CAN) were retrospectively analyzed from 15 Italian tertiary referral centers.
Results: Seventy seven patients were enrolled for a total of 86 treatment courses.
The cumulative retention rate of the IL-1 inhibitors at 12-, 24-, 48-, and 60-months
of follow-up was 79.9, 59.5, 53.5, and 53.5%, respectively, without any statistically
significant differences between ANA and CAN (p = 0.056), and between patients
treated in monotherapy compared to the subgroup co-administered with conventional
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immunosuppressors (p = 0.058). On the contrary, significant differences were found
between biologic-naive patients and those previously treated with biologic drugs
(p = 0.038) and when distinguishing according to adverse events (AEs) occurrence
(p = 0.04). In regression analysis, patients pre-treated with other biologics (HR = 3.357
[CI: 1.341–8.406], p = 0.01) and those experiencing AEs (HR = 2.970 [CI: 1.186–7.435],
p = 0.020) were associated with a higher hazard ratio of IL-1 inhibitors withdrawal.
The mean treatment delay was significantly higher among patients discontinuing IL-1
inhibitors (p = 0.0002).
Conclusions: Our findings suggest an excellent overall DRR for both ANA and CAN that
might be further augmented by paying attention to AEs and employing these agents as
first-line biologics in an early disease phase.
Keywords: systemic juvenile idiopathic arthritis, interleukin 1-beta, therapy, anakinra, canakinumab, drug
retention rate
INTRODUCTION
Systemic onset-juvenile idiopathic arthritis (sJIA) is the most
severe and distinct category of JIA due to its unique pathogenesis,
severity and disproportionately high morbidity and mortality
rates when compared to other JIA subtypes (Ruperto et al.,
2012; Minoia et al., 2014; Kumar, 2016; Davies et al.,
2017). This condition is distinguished by its unique clinical
features and treatment responses, that make it similar to the
autoinflammatory diseases, a large family of pathologic entities
caused by dysregulation of the innate immune system leading
to recurrent or continuous inflammation (Rigante, 2017, 2018).
Treatment of sJIA is often challenging and, when long-term
administration of corticosteroids (CS) is needed, conventional
disease modifying anti-rheumatic drugs (cDMARDs) or biologic
drugs should be introduced to replace or at least reduce
CS daily intake. Furthermore, patients affected by sJIA are
often recalcitrant to traditional/standard therapies (Cimaz,
2016; Mauro et al., 2017). Recent genetic and immunologic
studies have disclosed the emerging role of interleukin (IL)-
1 and genetic polymorphisms in promoter elements and
genes of IL-1 family into sJIA pathogenesis, reporting an
altered innate immune response with overproduction of IL-
1, IL-6, and IL-18 (Mellins et al., 2011). This has been
translated into clinical practice via cytokine-targeted treatments,
particularly with IL-1 inhibitors after showing their paramount
clinical efficacy in patients with cryopyrin-associated periodic
syndrome (Cantarini et al., 2011). The advent of biologic
agents has revolutionized therapeutic approaches in sJIA as
their introduction has been shown to modify disease course
and improve overall outcomes, particularly when initiated early
(Nigrovic et al., 2011; Hedrich et al., 2012; Vastert et al., 2014;
Pardeo et al., 2015). Several studies also including randomized
clinical trials display promising results of IL-1 blocking agents
in the management of this severe disease (Quartier et al.,
2011; Ruperto et al., 2012; Vastert et al., 2014; Feist et al.,
2018).
However, while robust evidence from randomized
clinical trials is available in the medical literature, only a
small amount of real-life data has been published so far,
especially in the context of early treatment, and few of
them have marginally investigated anti-IL-1 agents drug
retention rate (DRR) on a relatively long-term follow-up.
On this basis, we herein report our multicenter experience
on a patients affected by sJIA treated with the anti-IL-1
agents anakinra (ANA) and canakinumab (CAN), focusing
on their long-term effectiveness and predictive factors of
discontinuation.
MATERIALS AND METHODS
Study Design and Participants
Medical records of 76 patients affected by sJIA enrolled from
January 2008 until July 2016 in 15 Italian tertiary referral centers
were retrospectively reviewed. The following demographic,
clinical, and therapeutic data were collected: age, gender, age
at disease onset, disease duration, treatment delay, the anti-
IL-1 agent employed, dosages used, concomitant and previous
treatments, anti-IL 1 treatment duration, and reasons for
discontinuation.
All patients were diagnosed according to the revised
International League of Association for Rheumatology (ILAR)
criteria (Petty et al., 2004). In accordance with the best
standards of care, they were systematically followed-up every
3 months and/or in case of necessity (disease flare and/or safety
issues). Before starting anti-IL-1 treatment with ANA or CAN,
patients underwent a complete medical examination, evaluation
of hepatitis B and hepatitis C virus markers, urine culture,
QuantiFERON test and chest X-ray to rule out active or latent
infections. ANA and CAN dosages ranged from 1 to 4 mg/kg
and from 2 mg/kg every 8 weeks to 4 mg/kg every 4 weeks,
respectively.
Protocol Approval
This study adhered to the tenets of the Declaration of Helsinki
and the protocol was approved by the local Ethic Committee
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(reference number: 364-16OCT2013). Written informed consent
was obtained from all patients’ legal guardians.
Aims and Endpoints
The primary aim of the study was to examine the overall
DRR of IL-1 blockers in sJIA patients. Secondary aims of
our study were to: (i) explore the influence of biologic
line of treatment, adverse events (AEs), type of anti-IL-
1 agent, and the concomitant use of cDMARDs on DRR;
(ii) find eventual predictive factors associated with events
leading to drug discontinuation. The CS sparing effect and
the impact of disease duration and treatment delay on
survival constituted ancillary aims. The primary endpoint was
evaluated by Kaplan–Meier survival curve at 12-, 24-, -48,
and 60-months of follow-up. Secondary endopoints were as
follows: (i) using limit estimators to compare survival curves
according to AEs, ANA vs. CAN, monotherapy vs. combination
therapy with cDMARDs and significant differences on survival
curves distinguishing between biologic-naive patients and those
already treated with other biologics; (ii) to evaluate whether
demographic, clinical, and therapeutic variables could predict
time to treatment discontinuation. Finally, the ancillary aims
were explored by any potential statistically significant differences
in the mean disease duration and in the mean treatment
delay, subdividing our sample in patients continuing and
those discontinuing the treatment as well as on CS-sparing
effect.
Statistical Analysis
Data were analyzed using IBMSPSS Statistics for Windows,
version 24 (IBM Corp., Armonk, NY, United States). Descriptive
statistics was employed to display mean and standard deviation
(SD) or median and interquartile range (IQR) as appropriate.
Shapiro–Wilk test is the test by which we assessed the normality
of our data. Categorical variables were analyzed by Pearson’s
chi-square test, and McNemar test for repeated measures, while
differences in means were investigated with Mann–Whitney
U test. Survival analysis were carried out with Kaplan–Meier
curves with the event being ANA or CAN discontinuation.
Patients discontinuing treatment due to remission were not
included in the statistical analysis. Survival curves were compared
using both long-rank and Breslow test as limit estimators.
Event-free survival was assessed with a Cox proportional
hazard model using 95% confidence interval for hazard ratios
aiming to evaluate any relation of demographic, clinical
and therapeutic data with DRR. The threshold for statistical
significance was set to p < 0.05 and all p-values were two-
sided.
RESULTS
We studied 86 treatment regimens administered in a
cohort of 77 pediatric patients (34 males, 43 females)
receiving anti-IL-1 agents from January 2008 to July 2016.
Demographic, clinical and therapeutic data are shown in
Table 1. ANA and CAN were used in 61 and 25 regimens,
respectively. The mean ± SD time of treatment duration was
22.67 ± 19.50 months. The median age ± IQR at disease onset
was 6.00± 7.10 years.
The cumulative retention rate of both anti-IL-1 agents at
12-, 24-, 48-, and 60-months of follow-up was 79.9, 59.5, 53.5,
and 53.5%, respectively (Figure 1). Twenty-two out of 77 patients
were co-administered with cDMARDs, and 22 subjects had
been previously exposed to other biologic drugs. Statistically
significant differences were observed between biologic-naive
patients and those previously treated with biologic drugs
(p = 0.038) (Figure 2A). As illustrated in Figure 2B, the DRR of
IL-1 blockers resulted significantly different when separating the
cohort according to the occurrence of AEs (Breslow test p = 0.006
and log-rank p = 0.004). Contrarily, no statistically significant
TABLE 1 | Demographic, clinical and therapeutic data of our cohort of patients
affected with sJIA.
Patients no. 77
Male/female no. 34/43
Mean age ± SD 12.71 ± 6.65
Age at onset (median ± IQR) 5.65 ± 7.40
Age at diagnosis (median ± IQR) 5.75 ± 7.48
Disease duration (median ± IQR) 4.00 ± 5.95
Treatment delay (median ± IQR) 2.33 ± 6.31
Previous biologics ETN (n = 13); IFX (n = 3); ADA (n = 4);
TCZ (n = 5); ABA (n = 3); RTX (n = 2);
GOL (n = 2); CZP (n = 1)
Concomitant cDMARDs MTX (n = 12); CsA (n = 11); SSZ (n = 1);
LFN (n = 1); HCQ (n = 1)
ABA, abatacept; ADA, adalimumab; cDMARDs, conventional disease modifying
anti-rheumatic drugs; CsA, cyclosporine; CZP, certolizumab; ETN, etanercept;
GOL, golimumab; HCQ, hydroxychloroquine; IFX, infliximab; IQR, interquartile
range; LFN, leflunomide; MTX, methotrexate; RTX, rituximab; SD, standard
deviation; sJIA, systemic-onset juvenile idiopathic arthritis; SSZ, sulfasalazine; TCZ,
tocilizumab.
FIGURE 1 | Kaplan–Meier curve related to the overall cumulative drug
retention rate of interleukin-1 inhibitors in the whole cohort of patients with
systemic onset-juvenile idiopathic arthritis. Time 0 represents the beginning of
therapy with the event being the treatment discontinuation.
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FIGURE 2 | Kaplan–Meier curves describing the cumulative survival of interleukin-1 (IL-1) inhibitors according to: (A) biologic line of treatment, (B) occurrence of
AEs, (C) type of anti-IL-1 agent employed, (D) concomitant use cDMARDs or monotherapy with biologic agents. AEs, adverse events; ANA, anakinra; CAN,
canakinumab; cDMARDs, conventional disease modifying anti-rheumatic drugs.
differences were detected between ANA and CAN (p = 0.056)
(Figure 2C), and between patients treated in monotherapy
compared to the subgroup co-administered with cDMARDs
(p = 0.058) (Figure 2D), while Cox regression analysis identified
two variables associated with a higher hazard of treatment
withdrawal: biologic line, with a higher hazard for biologic-
exposed patients (HR = 3.357 [CI: 1.341–8.406], p = 0.01)
and the occurrence of AEs (HR = 2.970 [CI: 1.186–7.435],
p = 0.020).
Additionally, the median disease duration was significantly
higher among patients discontinuing IL-1 blockers
(5.88 years ± 6.55) compared to the subgroup that was
able to retain these biologic agents (3.17 years ± 3.68)
(p = 0.011). This difference was also found with regard
to treatment delay, which was significantly higher in
the subgroup of patients discontinuing anti-IL-1 agents
(3.71 years ± 6.07) vs. (1.18 years ± 2.53) of those still on
treatment (p = 0.0002).
With regard to the CS-sparing effect, a significant reduction
in the number of patients requiring the support of CS was
found (p = 0.025). Sixteen out of 63 patients (27%) were able to
completely discontinue CS therapy.
The AEs occurred in 13 out of 77 patients (17.1%) (11 on
ANA and 2 on CAN), with the most frequent being injection
site-reactions (n = 7), followed by generalized skin rashes (n = 4),
respiratory problems (n = 1), and abnormal level of liver enzymes
(n = 1). Two patients exhibiting generalized skin rash presented
also diarrhea. Overall, AEs were responsible for 10 cases of
treatment discontinuation. Figure 3 shows the reasons for
treatment discontinuation. No serious AEs were recorded, and
none of our patients developed macrophage activation syndrome
during the follow-up period.
DISCUSSION
Among the JIA spectrum, the systemic category represents
a difficult-to-manage condition not only from a diagnostic
perspective, due to the absence of pathognomonic clinical
features or laboratory markers forcing the clinician to perform
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FIGURE 3 | Reasons for discontinuation in sJIA patients.
a thorough diagnostic work-up, but also from a therapeutic
viewpoint. In the pre-biologic era, CS have been the sole effective
treatment option for many years, and the mainstay of therapy
in most patients with sJIA, while cDMARDs and some newer
alternatives such as anti-tumor necrosis factor-α agents had
provided unsatisfactory results (Russo and Katsicas, 2009; Stoll
and Cron, 2014). Pathogenetic evidence suggesting a prominent
role of IL-1 in sJIA pathways has given the rationale for specific
cytokine-targeted agents (Mellins et al., 2011). From the first
observation of a successful treatment of sJIA with IL-1 inhibition
in 2004 (Verbsky and White, 2004), a growing body of evidences
confirming the efficacy of anti-IL-1 agents has matured over
time (Lequerré et al., 2008; Quartier et al., 2011; Ruperto et al.,
2012; Vastert et al., 2014; Pardeo et al., 2015; Feist et al.,
2018).
In the present study we have reported the real-life experience
of 15 Italian tertiary referral centers with IL-1 inhibitors used
in the treatment of sJIA, focusing on long-term effectiveness
expressed as DRR.
Our findings suggest an excellent DRR with an estimated
probability greater than 50% to continue the treatment after
5 years from the start. The DRR tends to decrease in the
1st years of treatment and subsequently stabilizes: this may
be at least partially explained by the higher risk of AEs
during the initial period, which decreases over time from
the initiation of IL-1 inhibition, as reported in a previous
paper investigating safety profile of IL-1 blockade (Sota
et al., 2018). Indeed, safety issues determined a significant
decrease in DRR not only on the long-term, but also in
the beginning of anti-IL-1 therapy, as shown in the survival
curves.
Nonetheless, difficulties were encountered in comparing our
results with the available medical literature due to different
outcome measures and biologics administered as well as
heterogeneity of populations enrolled in the other studies
without a specific investigation on sJIA. Only a few studies
have investigated DRR in JIA patients (Tynjälä et al., 2009;
Otten et al., 2013). Otten et al. (2013) reported 17 cases of
sJIA treated with second or third line ANA, which presented
a superior DRR compared to a second TNF-α blocker and
reported that the effectiveness of a second biologic agent
seemed low, especially in the case of discontinuation of the
primary biologic agent due to inefficacy. In line with this
notion, our findings suggest a better DRR of IL-1 inhibitors
when used in biologic-naive patients. Other authors have also
recommended to administer IL-1 inhibitors as first-line agents
instead of a rescue therapy (Nigrovic et al., 2011; Hedrich
et al., 2012; Vastert et al., 2014; Pardeo et al., 2015), which
is also contemplated in the new ACR recommendations for
the treatment of sJIA (Ringold et al., 2013). Another relevant
issue concerns the need for a timely introduction of modern
cytokine-blocking strategies to prevent or at least minimize
structural damage due to long-term disease and treatment-
related AEs. Our data highlight the significant impact of
treatment delay in DRR of IL-1 inhibitors. Indeed, early IL-1
blockade may take advantage of the “window of opportunity”
and modify disease evolution (Nigrovic, 2014), while avoiding
long-term sequelae which have proven to be detrimental in
a limited-resource setting where early diagnosis or access
to multidisciplinary care and to biologics are still obstacles
to overcome (Dewoolkar et al., 2017). A more chronic and
persistent disease course has been associated with a delay in
diagnosis and consequently in starting an appropriate treatment.
On the other hand, earlier treatment has been associated
with better outcomes (Pardeo et al., 2015; Dewoolkar et al.,
2017). This may be attributable, as suggested by several
authors, to the unique pathogenesis of sJIA, which has been
hypothesized to be predominantly autoinflammatory in its
early stages explaining the better outcome for IL-1 blockade
in this phase (Nigrovic, 2014; Pardeo et al., 2017). Timely
treatment is imperative also for minimizing CS exposure
and CS-related deleterious AEs. In particular, we found a
significant lower number of patients on CS at the last follow-
up visit, which is of crucial importance in the pediatric
age.
We observed an excellent safety profile of ANA and CAN,
that were well-tolerated without any serious AEs and no case of
macrophage activation syndrome.
Limitations of our study includes the not randomized
retrospective design along with its inherent associated
drawbacks, and the difficulties for a valid comparison
with the available literature due to different endpoints.
Although the vast majority of patients were treated with
standard dosages, a few subjects were administered with
higher dosages. However, the small sample size of patients
administered with non-standard dosages did not allow
to perform a reliable statistical analysis. In addition, the
decision on when to start the treatment was made by the
local physician without any predefined criteria. To the
best of our knowledge, this is the first study to report
the long-term effectiveness in terms of DRR of anti-IL-1
agents in a cohort of patients diagnosed with sJIA.
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CONCLUSION
Despite remaining a major therapeutic challenge in pediatric
rheumatology, sJIA may be currently managed with new
biotechnologic drugs, including anti-IL-1 agents, which allow to
improve long-term outcome as well as to minimize long-term
exposure to CS. Indeed, our results have shown an excellent
overall retention rate of the IL-1 inhibitors ANA and CAN. Both
IL-1 inhibitors showed a similar DRR, and their survival was
not affected by the concomitant use of cDMARDs. These data
highlight the effectiveness of these agents in sJIA patients as
monotherapy. A close attention on safety concerns is warranted,
especially in the 1st year after treatment initiation. On the other
hand, the retention rate of anti IL-1 agents was influenced
by the different line of biologic therapy, suggesting that ANA
and CAN should be used as first-line biologics. Finally, our
results have displayed a significant impact of treatment delay
in drug discontinuation. Indeed, early treatment may take
advantage of the “windows of opportunity,” but this hypothesis
is far from being proven and requires further studies for its
corroboration.
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